 |
15 Diseases |  |
2 Trials |
|
2 Trials |  |
178 News |  |
| «12 |
- | alvelestat (MPH966) / Mereo Biopharma
Trial completion date: Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Oct 30, 2020
P1b/2, N=34, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2022 --> Dec 2021
- | alvelestat (MPH966) / Mereo Biopharma
Trial completion date, Trial primary completion date: Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Oct 19, 2020
P1b/2, N=34, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2022 --> Dec 2021 Trial completion date: Sep 2020 --> Dec 2022 | Trial primary completion date: Sep 2020 --> Dec 2021
- || alvelestat (AZD9668) / AstraZeneca, Mereo Biopharma
Enrollment open: COSTA: COVID-19 Study of Safety and Tolerability of Alvelestat (clinicaltrials.gov) - Oct 19, 2020
P1/2, N=15, Recruiting, Sponsor: University of Alabama at Birmingham
Trial completion date: Sep 2020 --> Dec 2022 | Trial primary completion date: Sep 2020 --> Dec 2021 Not yet recruiting --> Recruiting
- || alvelestat (AZD9668) / AstraZeneca, Mereo Biopharma
New P1/2 trial: COSTA: COVID-19 Study of Safety and Tolerability of Alvelestat (clinicaltrials.gov) - Sep 7, 2020
P1/2, N=15, Not yet recruiting, Sponsor: University of Alabama at Birmingham
- | alvelestat (AZD9668) / AstraZeneca, Mereo Biopharma
Enrollment change, Trial withdrawal: MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Mar 20, 2020
P1/2, N=0, Withdrawn, Sponsor: Nelson Chao
Not yet recruiting --> Recruiting N=72 --> 0 | Not yet recruiting --> Withdrawn
- | alvelestat (AZD9668) / AstraZeneca, Mereo Biopharma
Trial completion date, Trial primary completion date: ASTRAEUS: A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. (clinicaltrials.gov) - Oct 15, 2019
P2, N=165, Recruiting, Sponsor: Mereo BioPharma
N=72 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Oct 2019 --> Jul 2020 | Trial primary completion date: Sep 2019 --> Jun 2020
- alvelestat (AZD9668) / AstraZeneca, Mereo Biopharma
Inhibition of Neutrophil Elastase Reduces Autoantibody Levels and Renal Inflammation in Murine Lupus (A302) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3784;
Treatment of MRL-lpr mice with two distinct orally-bioavailable NE inhibitors (GW311616A or Alvelestat) led to the reduction in autoantibody levels, decreased immune-cell infiltration into kidneys, and altered immune-cell profiles in lymph nodes. These data provide further evidence that NE is a valid therapeutic target in lupus, and perhaps especially as a strategy for preventing lupus nephritis.
- ||| NN1213 / Novo Nordisk, alvelestat (MPH966) / Mereo Biopharma
Trial completion, Enrollment change: Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes (clinicaltrials.gov) - Jun 21, 2019
P2, N=14, Completed, Sponsor: Nick Giannoukakis, PhD
These data provide further evidence that NE is a valid therapeutic target in lupus, and perhaps especially as a strategy for preventing lupus nephritis. Active, not recruiting --> Completed | N=42 --> 14
- |||| alvelestat (AZD9668) / AstraZeneca, Mereo Biopharma
New P1/2 trial: MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jun 13, 2019
P1/2, N=72, Not yet recruiting, Sponsor: Nelson Chao
- ||| alvelestat (MPH966) / Mereo Biopharma
Enrollment open: ATALANTa: Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency (clinicaltrials.gov) - Apr 10, 2019
P2, N=66, Recruiting, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed | N=42 --> 14 Not yet recruiting --> Recruiting
- | alvelestat (MPH966) / Mereo Biopharma
Trial completion date, Trial initiation date, Trial primary completion date: Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Nov 9, 2018
P1b/2, N=34, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial completion date: Sep 2019 --> Sep 2020 | Initiation date: Jan 2016 --> Apr 2016 | Trial primary completion date: Sep 2019 --> Sep 2020
- | alvelestat (MPH966) / Mereo Biopharma
Trial primary completion date: Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Oct 15, 2018
P1b/2, N=34, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2019 --> Sep 2020 | Initiation date: Jan 2016 --> Apr 2016 | Trial primary completion date: Sep 2019 --> Sep 2020 Trial primary completion date: Sep 2018 --> Sep 2019
- ||| alvelestat (AZD9668) / AstraZeneca, Mereo Biopharma
Enrollment open: ASTRAEUS: A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. (clinicaltrials.gov) - Sep 28, 2018
P2, N=165, Recruiting, Sponsor: Mereo BioPharma
Trial primary completion date: Sep 2018 --> Sep 2019 Not yet recruiting --> Recruiting
- | alvelestat (MPH966) / Mereo Biopharma
New P2 trial: ATALANTa: Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency (clinicaltrials.gov) - Sep 19, 2018
P2, N=66, Not yet recruiting, Sponsor: University of Alabama at Birmingham
- |||| alvelestat (AZD9668) / AstraZeneca, Mereo Biopharma
New P2 trial: ASTRAEUS: A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. (clinicaltrials.gov) - Aug 16, 2018
P2, N=165, Not yet recruiting, Sponsor: Mereo BioPharma
- | NN1213 / Novo Nordisk, alvelestat (MPH966) / Mereo Biopharma
Enrollment closed: Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes (clinicaltrials.gov) - May 30, 2018
P2, N=42, Active, not recruiting, Sponsor: Nick Giannoukakis, PhD
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- alvelestat (AZD9668) / AstraZeneca, Mereo Biopharma
Trial primary completion date: Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes (clinicaltrials.gov) - Dec 7, 2017
P2, N=42, Recruiting, Sponsor: Nick Giannoukakis, PhD
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2017 --> Mar 2019
- | alvelestat (MPH966) / Mereo Biopharma
Trial primary completion date: Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Oct 7, 2017
P1b/2, N=34, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2017 --> Mar 2019 Trial primary completion date: Sep 2017 --> Sep 2018
- alvelestat (MPH966) / Mereo Biopharma
Phase classification: Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Aug 9, 2016
P1b/2, N=34, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2017 --> Sep 2018 Phase classification: P1/2 --> P1b/2
- alvelestat (MPH966) / Mereo Biopharma
New P1/2 trial: Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Feb 1, 2016
P1/2, N=34, Recruiting, Sponsor: National Cancer Institute (NCI)
- | alvelestat (AZD9668) / AstraZeneca, Mereo Biopharma
Enrollment open: Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes (clinicaltrials.gov) - Dec 4, 2015
P2, N=42, Recruiting, Sponsor: Nick Giannoukakis, PhD
Phase classification: P1/2 --> P1b/2 Not yet recruiting --> Recruiting
- | alvelestat (AZD9668) / AstraZeneca, Mereo Biopharma
New P2 trial: Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes (clinicaltrials.gov) - Nov 6, 2015
P2, N=42, Not yet recruiting, Sponsor: Nick Giannoukakis, PhD
- alvelestat (MPH966) / Mereo Biopharma
Enrollment change: A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin (clinicaltrials.gov) - Jan 27, 2013
P1, N=0, Withdrawn, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting N=15 --> 0
- ||| alvelestat (AZD9668) / AstraZeneca, Mereo Biopharma
Enrollment change: Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients (clinicaltrials.gov) - Jun 18, 2012
P2, N=52, Completed, Sponsor: AstraZeneca
N=15 --> 0 N=109 --> 52
- ||| alvelestat (AZD9668) / AstraZeneca, Mereo Biopharma
Enrollment change: INCA: A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis (clinicaltrials.gov) - Jun 18, 2012
P2, N=56, Completed, Sponsor: AstraZeneca
N=109 --> 52 N=70 --> 56